Table of Contents
International Scholarly Research Notices
Volume 2014, Article ID 123257, 11 pages
http://dx.doi.org/10.1155/2014/123257
Review Article

Natural Remedies for the Treatment of Beta-Thalassemia and Sickle Cell Anemia—Current Status and Perspectives in Fetal Hemoglobin Reactivation

1School of Life Sciences, The Chinese University of Hong Kong, Shatin, New Territories, Hong Kong
2Institute of Chinese Medicine, The Chinese University of Hong Kong, Shatin, New Territories, Hong Kong
3CUHK Shenzhen Research Institute, The Chinese University of Hong Kong, Shenzhen, Hong Kong

Received 18 April 2014; Revised 21 July 2014; Accepted 25 July 2014; Published 2 October 2014

Academic Editor: David Murphy

Copyright © 2014 Noel Yat Hey Ng and Chun Hay Ko. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. K. Liu, H. Xing, S. Zhang, S. M. Liu, and M. C. Fung, “Cucurbitacin D induces fetal hemoglobin synthesis in K562 cells and human hematopoietic progenitors through activation of p38 pathway and stabilization of the γ-globin mRNA,” Blood Cells, Molecules, and Diseases, vol. 45, no. 4, pp. 269–275, 2010. View at Publisher · View at Google Scholar · View at Scopus
  2. B. E. Glader and K. A. Look, “Hematologic disorders in children from Southeast Asia,” Pediatric Clinics of North America, vol. 43, no. 3, pp. 665–681, 1996. View at Publisher · View at Google Scholar · View at Scopus
  3. A. H. Khelil, S. Denden, N. Leban et al., “Hemoglobinopathies in North Africa: a review,” Hemoglobin, vol. 34, no. 1, pp. 1–23, 2010. View at Publisher · View at Google Scholar · View at Scopus
  4. C. Kattamis and A. C. Kattamis, “Genotypes and phenotypes of beta-thalassemia in Mediterranean populations,” Journal of Pediatric Hematology/Oncology, vol. 14, no. 3, pp. 7–9, 1997. View at Google Scholar
  5. R. Mabaera, R. J. West, S. J. Conine et al., “A cell stress signaling model of fetal hemoglobin induction: what doesn't kill red blood cells may make them stronger,” Experimental Hematology, vol. 36, no. 9, pp. 1057–1072, 2008. View at Publisher · View at Google Scholar · View at Scopus
  6. R. L. Nagel and E. F. Roth Jr., “Malaria and red cell genetic defects,” Blood, vol. 74, no. 4, pp. 1213–1221, 1989. View at Google Scholar · View at Scopus
  7. M. Aidoo, D. J. Terlouw, M. S. Kolczak et al., “Protective effects of the sickle cell gene against malaria morbidity and mortality,” The Lancet, vol. 359, no. 9314, pp. 1311–1312, 2002. View at Publisher · View at Google Scholar · View at Scopus
  8. A. El-Beshlawy, M. Hamdy, and M. El Ghamrawy, “Fetal globin induction in βthalassemia,” Hemoglobin, vol. 33, no. 1, pp. S197–S203, 2009. View at Publisher · View at Google Scholar · View at Scopus
  9. D. J. Weatherall and J. B. Clegg, “The thalassemia syndromes,” in The Thalassemia Syndromes, D. J. Weatherall and B. Clegg, Eds., pp. 287–356, Blackwell Science, 4th edition, 2001. View at Google Scholar
  10. D. R. Higgs, S. L. Thein, and W. G. Woods, “The physiology of the thalassemia,” in The Thalassemia Syndromes, D. J. Weatherall and B. Clegg, Eds., pp. 265–284, Blackwell Science, 4th edition, 2001. View at Google Scholar
  11. S. L. Schrier, “Pathophysiology of thalassemia,” Current Opinion in Hematology, vol. 9, no. 2, pp. 123–126, 2002. View at Publisher · View at Google Scholar · View at Scopus
  12. S. Gardenghi, M. F. Marongiu, P. Ramos et al., “Ineffective erythropoiesis in β-thalassemia is characterized by increased iron absorption mediated by down-regulation of hepcidin and up-regulation of ferroportin,” Blood, vol. 109, no. 11, pp. 5027–5035, 2007. View at Publisher · View at Google Scholar · View at Scopus
  13. N. Bianchi, C. Zuccato, I. Lampronti, M. Borgatti, and R. Gambari, “Fetal hemoglobin inducers from the natural world: a novel approach for identification of drugs for the treatment of β-thalassemia and Sickle-cell anemia,” Evidence-based Complementary and Alternative Medicine, vol. 6, no. 2, pp. 141–151, 2009. View at Publisher · View at Google Scholar · View at Scopus
  14. A. Kutlar, “Sickle cell disease: a multigenic perspective of a single gene disorder,” Hemoglobin, vol. 31, no. 2, pp. 209–224, 2007. View at Publisher · View at Google Scholar · View at Scopus
  15. T. E. Delea, J. Edelsberg, O. Sofrygin et al., “Consequences and costs of noncompliance with iron chelation therapy in patients with transfusion-dependent thalassemia: a literature review,” Transfusion, vol. 47, no. 10, pp. 1919–1929, 2007. View at Publisher · View at Google Scholar · View at Scopus
  16. M. Bhatia and M. C. Walters, “Hematopoietic cell transplantation for thalassemia and sickle cell disease: Past, present and future,” Bone Marrow Transplantation, vol. 41, no. 2, pp. 109–117, 2008. View at Publisher · View at Google Scholar · View at Scopus
  17. S. Shenoy, “Has stem cell transplantation come of age in the treatment of sickle cell disease?” Bone Marrow Transplantation, vol. 40, no. 9, pp. 813–821, 2007. View at Publisher · View at Google Scholar · View at Scopus
  18. M. C. Walters, M. Patience, W. Leisenring et al., “Barriers to bone marrow transplantation for sickle cell anemia,” Biology of Blood and Marrow Transplantation, vol. 2, no. 2, pp. 100–104, 1996. View at Google Scholar · View at Scopus
  19. M. Sadelain, “Recent advances in globin gene transfer for the treatment of beta-thalassemia and sickle cell anemia,” Current Opinion in Hematology, vol. 13, no. 3, pp. 142–148, 2006. View at Publisher · View at Google Scholar · View at Scopus
  20. S. Fang, Z. Wu, X. Zhang et al., “Clinical observation on YiSuiShengXueGranule on treating 156 patients with β-thalassemia major and the molecular mechanism study,” Biological and Pharmaceutical Bulletin, vol. 30, no. 11, pp. 2084–2087, 2007. View at Publisher · View at Google Scholar · View at Scopus
  21. C. E. Dunbar, “The yin and yang of stem cell gene therapy: insights into hematopoiesis, leukemogenesis, and gene therapy safety,” Hematology, pp. 460–465, 2007. View at Google Scholar · View at Scopus
  22. P. W. Hargrove, S. Kepes, H. Hanawa et al., “Globin lentiviral vector insertions can perturb the expression of endogenous genes in β-thalassemic hematopoietic cells,” Molecular Therapy, vol. 16, no. 3, pp. 525–533, 2008. View at Publisher · View at Google Scholar · View at Scopus
  23. B. G. Forget, “Molecular basis of hereditary persistence of fetal hemoglobin,” Annals of the New York Academy of Sciences, vol. 850, pp. 38–44, 1998. View at Publisher · View at Google Scholar · View at Scopus
  24. U. Bhardwaj and E. R. B. McCabe, “Multiplex-PCR assay for the deletions causing hereditary persistence of fetal hemoglobin,” Molecular Diagnosis, vol. 9, no. 3, pp. 151–156, 2005. View at Publisher · View at Google Scholar · View at Scopus
  25. L. R. Liu, Z. W. Du, H. L. Zhao et al., “T to C substitution at -175 or -173 of the γ-globin promoter affects GATA-1 and Oct-1 binding in vitro differently but can independently reproduce the hereditary persistence of fetal hemoglobin phenotype in transgenic mice,” The Journal of Biological Chemistry, vol. 280, no. 9, pp. 7452–7459, 2005. View at Publisher · View at Google Scholar · View at Scopus
  26. C. Garner, T. K. Dew, R. Sherwood, D. Rees, and S. L. Thein, “Heterocellular hereditary persistence of fetal haemoglobin affects the haematological parameters of β-thalassaemia trait,” British Journal of Haematology, vol. 123, no. 2, pp. 353–358, 2003. View at Publisher · View at Google Scholar · View at Scopus
  27. E. Gallo, P. Massaro, R. Miniero, D. David, and C. Tarella, “The importance of the genetic picture and globin synthesis in determining the clinical and haematological features of thalassaemia intermedia,” British Journal of Haematology, vol. 41, no. 2, pp. 211–221, 1979. View at Publisher · View at Google Scholar · View at Scopus
  28. S. A. Ali, “Milder variant of sickle-cell disease in Arabs in Kuwait associated with unusually high level of foetal haemoglobin,” British Journal of Haematology, vol. 19, no. 5, pp. 613–619, 1970. View at Publisher · View at Google Scholar · View at Scopus
  29. W. G. Wood, J. B. Clegg, and D. J. Weatherall, “Hereditary persistence of fetal hemoglobin (HPFH) and δβ thalassemia,” British Journal of Haematology, vol. 43, no. 4, pp. 509–520, 1979. View at Publisher · View at Google Scholar · View at Scopus
  30. S. Zein, W. Li, V. Ramakrishnan et al., “Identification of fetal hemoglobin-inducing agents using the human leukemia KU812 cell line,” Experimental Biology and Medicine, vol. 235, no. 11, pp. 1385–1394, 2010. View at Publisher · View at Google Scholar · View at Scopus
  31. H. Li, C. H. Ko, S. Y. Tsang, P. C. Leung, M. C. Fung, and K. P. Fung, “The ethanol extract of Fructus trichosanthis promotes fetal hemoglobin production via p38 MAPK activation and Erk inactivation in K562 cells,” Evidence-Based Complementary and Alternative Medicine, vol. 2011, Article ID 657056, 8 pages, 2011. View at Publisher · View at Google Scholar · View at Scopus
  32. N. F. Olivieri and D. J. Weatherall, “The therapeutic reactivation of fetal haemoglobin,” Human Molecular Genetics, vol. 7, no. 10, pp. 1655–1658, 1998. View at Publisher · View at Google Scholar · View at Scopus
  33. Y. Watanapokasin, S. Chuncharunee, D. Sanmund et al., “In vivo and in vitro studies of fetal hemoglobin induction by hydroxyurea in β-thalassemia/hemoglobin E patients,” Experimental Hematology, vol. 33, no. 12, pp. 1486–1492, 2005. View at Publisher · View at Google Scholar · View at Scopus
  34. P. Heller and J. DeSimone, “5-Azacytidine and fetal hemoglobin,” The American Journal of Hematology, vol. 17, no. 4, pp. 439–447, 1984. View at Publisher · View at Google Scholar · View at Scopus
  35. J. J. Strouse, S. Lanzkron, M. C. Beach et al., “Hydroxyurea for sickle cell disease: a systematic review for efficacy and toxicity in children,” Pediatrics, vol. 122, no. 6, pp. 1332–1342, 2008. View at Publisher · View at Google Scholar · View at Scopus
  36. M. L. Randi, E. Ruzzon, F. Tezza, G. Luzzatto, and F. Fabris, “Toxicity and side effects of hydroxyurea used for primary thrombocythemia,” Platelets, vol. 16, no. 3-4, pp. 181–184, 2005. View at Publisher · View at Google Scholar · View at Scopus
  37. H. G. Drexler, Y. Matsuo, and R. A. F. MacLeod, “Malignant hematopoietic cell lines: in vitro models for the study of erythroleukemia,” Leukemia Research, vol. 28, no. 12, pp. 1243–1251, 2004. View at Publisher · View at Google Scholar · View at Scopus
  38. J. L. Villeval, P. G. Pelicci, A. Tabilio et al., “Erythroid properties of K562 cells. Effect of hemin, butyrate and TPA induction,” Experimental Cell Research, vol. 146, no. 2, pp. 428–435, 1983. View at Publisher · View at Google Scholar · View at Scopus
  39. R. Gambari, L. del Senno, R. Barbieri et al., “Human leukemia K-562 cells: induction of erythroid differentiation by 5-azacytidine,” Cell Differentiation, vol. 14, no. 2, pp. 87–97, 1984. View at Publisher · View at Google Scholar · View at Scopus
  40. J. DeSimone, P. Heller, L. Hall, and D. Zwiers, “5-Azacytidine stimulates fetal hemoglobin synthesis in anemic baboons,” Proceedings of the National Academy of Sciences of the United States of America, vol. 79, no. 14, pp. 4428–4431, 1982. View at Publisher · View at Google Scholar · View at Scopus
  41. J. de Simone and A. L. Mueller, “Fetal hemoglobin (HbF) synthesis in baboons, Papio cynocephalus. Analysis of fetal and adult hemoglobin synthesis during fetal development,” Blood, vol. 53, no. 1, pp. 19–27, 1979. View at Google Scholar · View at Scopus
  42. J. DeSimone, S. I. Biel, and P. Heller, “Stimulation of fetal hemoglobin synthesis in baboons by hemolysis and hypoxia,” Proceedings of the National Academy of Sciences of the United States of America, vol. 75, no. 6, pp. 2937–2940, 1978. View at Publisher · View at Google Scholar · View at Scopus
  43. P. E. Nute, P. Chen, and G. Stamatoyannopoulos, “Acceleration of F-cell production in response to experimentally induced anemia in adult baboons (Papio cynocephalus),” American Journal of Hematology, vol. 8, no. 2, pp. 157–168, 1980. View at Publisher · View at Google Scholar · View at Scopus
  44. P. Constantoulakis, B. Josephson, L. Mangahas et al., “Locus control region-Aγ transgenic mice: a new model for studying the induction of fetal hemoglobin in the adult,” Blood, vol. 77, no. 6, pp. 1326–1333, 1991. View at Google Scholar · View at Scopus
  45. B. S. Pace, H. L. Elford, and G. Stamatoyannopoulos, “Transgenic mouse model of pharmacologic induction of fetal hemoglobin: studies using a new ribonucleotide reductase inhibitor, Didox,” American Journal of Hematology, vol. 45, no. 2, pp. 136–141, 1994. View at Publisher · View at Google Scholar · View at Scopus
  46. R. Gambari and E. Fibach, “Medicinal chemistry of fetal hemoglobin inducers for treatment of β-thalassemia,” Current Medicinal Chemistry, vol. 14, no. 2, pp. 199–212, 2007. View at Publisher · View at Google Scholar · View at Scopus
  47. S. P. Perrine, S. A. Castaneda, M. S. Boosalis, G. L. White, B. M. Jones, and R. Bohacek, “Induction of fetal globin in β-thalassemia: cellular obstacles and molecular progress,” Annals of the New York Academy of Sciences, vol. 1054, pp. 257–265, 2005. View at Publisher · View at Google Scholar · View at Scopus
  48. H. Cao, G. Stamatoyannopoulos, and M. Jung, “Induction of human γ globin gene expression by histone deacetylase inhibitors,” Blood, vol. 103, no. 2, pp. 701–709, 2004. View at Publisher · View at Google Scholar · View at Scopus
  49. E. Fibach, N. Bianchi, M. Borgatti et al., “Effects of rapamycin on accumulation of alpha-, beta- and gamma-globin mRNAs in erythroid precursor cells from beta-thalassaemia patients,” European Journal of Haematology, vol. 77, no. 5, pp. 437–441, 2006. View at Publisher · View at Google Scholar · View at Scopus
  50. N. Bianchi, F. Osti, C. Rutigliano et al., “The DNA-binding drugs mithramycin and chromomycin are powerful inducers of erythroid differentiation of human K562 cells,” British Journal of Haematology, vol. 104, no. 2, pp. 258–265, 1999. View at Publisher · View at Google Scholar · View at Scopus
  51. L. A. Moutouh-de Parseval, D. Verhelle, E. Glezer et al., “Pomalidomide and lenalidomide regulate erythropoiesis and fetal hemoglobin production in human CD34+ cells,” The Journal of Clinical Investigation, vol. 118, no. 1, pp. 248–258, 2008. View at Publisher · View at Google Scholar · View at Scopus
  52. B. A. Miller, S. P. Perrine, A. Bernstein et al., “Influence of steel factor on hemoglobin synthesis in sickle cell disease,” Blood, vol. 79, no. 7, pp. 1861–1868, 1992. View at Google Scholar · View at Scopus
  53. U. Wojda, K. R. Leigh, J. M. Njoroge et al., “Fetal hemoglobin modulation during human erythropoiesis: stem cell factor has “late” effects related to the expression pattern of CD117,” Blood, vol. 101, no. 2, pp. 492–497, 2003. View at Publisher · View at Google Scholar · View at Scopus
  54. M. Gabbianelli, O. Morsilli, A. Massa et al., “Effective erythropoiesis and HbF reactivation induced by kit ligand in β-thalassemia,” Blood, vol. 111, no. 1, pp. 421–429, 2008. View at Publisher · View at Google Scholar · View at Scopus
  55. R. M. Bohmer, “Reactivation of fetal hemoglobin in adult stem cell erythropoiesis by transforming growth factor-beta,” Journal of Hematotherapy and Stem Cell Research, vol. 12, no. 5, pp. 499–504, 2003. View at Publisher · View at Google Scholar · View at Scopus
  56. R. S. Weinberg, X. Ji, M. Sutton et al., “Butyrate increases the efficiency of translation of γ-globin mRNA,” Blood, vol. 105, no. 4, pp. 1807–1809, 2005. View at Publisher · View at Google Scholar · View at Scopus
  57. S. P. Perrine, G. Ginder, D. V. Faller et al., “A short-term trial of butyrate to stimulate fetal-globin-gene expression in the γ-globin disorders,” The New England Journal of Medicine, vol. 328, pp. 129–131, 1993. View at Google Scholar
  58. P. Constantoulakis, G. Knitter, and G. Stamatoyannopoulos, “On the induction of fetal hemoglobin by butyrates: in vivo and in vitro studies with sodium butyrate and comparison of combination treatments with 5-AzaC and AraC,” Blood, vol. 74, no. 6, pp. 1963–1971, 1989. View at Google Scholar · View at Scopus
  59. E. Liakopoulou, C. A. Blau, Q. Li et al., “Stimulation of fetal hemoglobin production by short chain fatty acids,” Blood, vol. 86, no. 8, pp. 3227–3235, 1995. View at Google Scholar · View at Scopus
  60. A. F. Collins, G. J. Dover, and N. L. C. Luban, “Increased fetal hemoglobin production in patients receiving valproic acid for epilepsy,” Blood, vol. 84, no. 5, pp. 1690–1691, 1994. View at Google Scholar · View at Scopus
  61. A. F. Collins, H. A. Pearson, P. Giardina, K. T. McDonagh, S. W. Brusilow, and G. J. Dover, “Oral sodium phenylbutyrate therapy in homozygous β thalassemia: a clinical trial,” Blood, vol. 85, no. 1, pp. 43–49, 1995. View at Google Scholar · View at Scopus
  62. T. Ikuta, Y. W. Kan, P. S. Swerdlow, D. V. Faller, and S. P. Perrine, “Alterations in protein-DNA interactions in the γ-globin gene promoter in response to butyrate therapy,” Blood, vol. 92, no. 8, pp. 2924–2933, 1998. View at Google Scholar · View at Scopus
  63. G. F. Atweh, M. Sutton, I. Nassif et al., “Sustained induction of fetal hemoglobin by pulse butyrate therapy in sickle cell disease,” Blood, vol. 93, no. 6, pp. 1790–1797, 1999. View at Google Scholar · View at Scopus
  64. E. Liakopoulou, Q. Li, and G. Stamatoyannopoulos, “Induction of fetal hemoglobin by propionic and butyric acid derivatives: correlations between chemical structure and potency of Hb F induction,” Blood Cells, Molecules and Diseases, vol. 29, no. 1, pp. 48–56, 2002. View at Publisher · View at Google Scholar · View at Scopus
  65. B. S. Pace, G. L. White, G. J. Dover, M. S. Boosalis, D. V. Faller, and S. P. Perrine, “Short-chain fatty acid derivatives induce fetal globin expression and erythropoiesis in vivo,” Blood, vol. 100, no. 13, pp. 4640–4648, 2002. View at Publisher · View at Google Scholar · View at Scopus
  66. W. Aerbajinai, J. Zhu, Z. Gao, K. Chin, and G. P. Rodgers, “Thalidomide induces gamma-globin gene expression through increased reactive oxygen species-mediated p38 MAPK signaling and histone H4 acetylation in adult erythropoiesis,” Blood, vol. 110, no. 8, pp. 2864–2871, 2007. View at Publisher · View at Google Scholar · View at Scopus
  67. M. Gabbianelli, O. Morsilli, A. Massa et al., “Effective erythropoiesis and HbF reactivation induced by kit ligand in β-thalassemia,” Blood, vol. 111, no. 1, pp. 421–429, 2008. View at Publisher · View at Google Scholar · View at Scopus
  68. R. M. Böhmer, “Reactivation of fetal hemoglobin in adult stem cell erythropoiesis by transforming growth factor-β,” Journal of Hematotherapy and Stem Cell Research, vol. 12, no. 5, pp. 499–504, 2003. View at Publisher · View at Google Scholar · View at Scopus
  69. A. Guerrini, I. Lampronti, N. Bianchi et al., “Bergamot (Citrus bergamia Risso) fruit extracts as γ-globin gene expression inducers: phytochemical and functional perspectives,” Journal of Agricultural and Food Chemistry, vol. 57, no. 10, pp. 4103–4111, 2009. View at Publisher · View at Google Scholar · View at Scopus
  70. E. W. Iyamu, E. A. Turner, and T. Asakura, “In vitro effects of NIPRISAN (Nix-0699): a naturally occurring, potent antisickling agent,” British Journal of Haematology, vol. 118, no. 1, pp. 337–343, 2002. View at Publisher · View at Google Scholar · View at Scopus
  71. E. W. Iyamu, E. A. Turner, and T. Asakura, “Niprisan (Nix-0699) improves the survival rates of transgenic sickle cell mice under acute severe hypoxic conditions,” British Journal of Haematology, vol. 122, no. 6, pp. 1001–1008, 2003. View at Publisher · View at Google Scholar · View at Scopus
  72. I. Lampronti, D. Martello, N. Bianchi et al., “In vitro antiproliferative effects on human tumor cell lines of extracts from the Bangladeshi medicinal plant Aegle marmelos Correa,” Phytomedicine, vol. 10, no. 4, pp. 300–308, 2003. View at Publisher · View at Google Scholar · View at Scopus
  73. I. Lampronti, N. Bianchi, M. Borgatti, E. Fibach, E. Prus, and R. Gambari, “Accumulation of γ-globin mRNA in human erythroid cells treated with angelicin,” European Journal of Haematology, vol. 71, no. 3, pp. 189–195, 2003. View at Publisher · View at Google Scholar · View at Scopus
  74. R. Gamabari, “Novel trends for the discovery and characterization of modifiers of globin gene expression,” in Proceedings of the 10th International Thalassemia Conference, Cairo, Egypt, May 2009.
  75. E. Fibach, N. Bianchi, M. Borgatti, E. Prus, and R. Gambari, “Mithramycin induces fetal hemoglobin production in normal and thalassemic human erythroid precursor cells,” Blood, vol. 102, no. 4, pp. 1276–1281, 2003. View at Publisher · View at Google Scholar · View at Scopus
  76. C. Zhang and Z. Wu, “Molecular pharmacological basis of the YiSui ShenXu Granule in β-thalassemia therapy,” Journal of Ethnopharmacology, vol. 120, no. 3, pp. 437–441, 2008. View at Publisher · View at Google Scholar · View at Scopus
  77. I. A. Aimola, H. M. Inuwa, A. J. Nok, and A. I. Mamman, “Induction of foetal aemoglobin synthesis in erythroid progenitor stem cells: mediated by water-soluble components of Terminalia catappa,” Cell Biochemistry and Function, vol. 32, pp. 361–367, 2014. View at Google Scholar
  78. S. J. Ameh, F. D. Tarfa, and B. U. Ebeshi, “Traditional herbal management of sickle cell anemia: lessons from Nigeria,” Anemia, vol. 2012, Article ID 607436, 9 pages, 2012. View at Publisher · View at Google Scholar · View at Scopus
  79. Z. Wu, X. Zhang, and M. Li, “Clinical observation on effects of Yisui Shengxue Granule in treating 156 patients with beta-thalassemia,” Zhongguo Zong Xi Yi Jie He Za Zhi, vol. 26, no. 4, pp. 352–354, 2006. View at Google Scholar · View at Scopus
  80. B. S. Pace, X. Qian, J. Sangerman et al., “p38 MAP kinase activation mediates γ-globin gene induction in erythroid progenitors,” Experimental Hematology, vol. 31, no. 11, pp. 1089–1096, 2003. View at Publisher · View at Google Scholar · View at Scopus
  81. G. Wei, G. Zhao, W. Song et al., “Mechanisms of human γ-globin transcriptional induction by apicidin involves p38 signaling to chromatin,” Biochemical and Biophysical Research Communications, vol. 363, no. 4, pp. 889–894, 2007. View at Publisher · View at Google Scholar · View at Scopus
  82. O. Witt, K. Sand, and A. Pekrun, “Butyrate-induced erythroid differentiation of human K562 leukemia cells involves inhibition of ERK and activation of p38 MAP kinase pathways,” Blood, vol. 95, no. 7, pp. 2391–2396, 2000. View at Google Scholar · View at Scopus
  83. G. H. Wei, G. W. Zhao, W. Song et al., “Mechanisms of human γ-globin transcriptional induction by apicidin involves p38 signaling to chromatin,” Biochemical and Biophysical Research Communications, vol. 363, no. 4, pp. 889–894, 2007. View at Publisher · View at Google Scholar · View at Scopus
  84. M. Politou, P. Kollia, S. Akel, Y. Papassotiriou, A. Stamoulakatou, and D. Loukopoulos, “Valproic acid, trichostatin and their combination with hemin preferentially enhance γ-globin gene expression in human erythroid liquid cultures,” Haematologica, vol. 86, no. 7, pp. 700–705, 2001. View at Google Scholar · View at Scopus
  85. J. J. Barrow, Y. Li, M. Hossain, S. Huang, and J. Bungert, “Dissecting the function of the adult β-globin downstream promoter region using an artificial zinc finger DNA-binding domain,” Nucleic Acids Research, vol. 42, no. 7, pp. 4363–4374, 2014. View at Google Scholar
  86. W. Shen, D. Liu, and C. Liang, “The regulatory network controlling β-globin gene switching,” Molecular Biology Reports, vol. 28, no. 3, pp. 175–183, 2001. View at Publisher · View at Google Scholar · View at Scopus
  87. V. G. Sankaran, J. Xu, and S. H. Orkin, “Advances in the understanding of haemoglobin switching: review,” British Journal of Haematology, vol. 149, no. 2, pp. 181–194, 2010. View at Publisher · View at Google Scholar · View at Scopus
  88. Y. Nagata, N. Takahashi, R. J. Davis, and K. Todokoro, “Activation of p38 MAP kinase and JNK but not ERK is required for erythropoietin-induced erythroid differentiation,” Blood, vol. 92, no. 6, pp. 1859–1869, 1998. View at Google Scholar · View at Scopus
  89. L. Chakalova, C. S. Osborne, Y. Dai et al., “The Corfu δβ thalassemia deletion disrupts γ-globin gene silencing and reveals post-transcriptional regulation of HbF expression,” Blood, vol. 105, no. 5, pp. 2154–2160, 2005. View at Publisher · View at Google Scholar · View at Scopus
  90. R. Mabaera, M. R. Greene, C. A. Richardson, S. J. Conine, C. D. Kozul, and C. H. Lowrey, “Neither DNA hypomethylation nor changes in the kinetics of erythroid differentiation explain 5-azacytidine's ability to induce human fetal hemoglobin,” Blood, vol. 111, no. 1, pp. 411–420, 2008. View at Publisher · View at Google Scholar · View at Scopus
  91. F. Morceau, C. Dupont, V. Palissot et al., “GTP-mediated differentiation of the human K562 cell line: transient overexpression of GATA-1 and stabilization of the γ-globin mRNA,” Leukemia, vol. 14, no. 9, pp. 1589–1597, 2000. View at Publisher · View at Google Scholar · View at Scopus
  92. A. Szulawska, J. Arkusinska, and M. Czyz, “Accumulation of gamma-globin mRNA and induction of irreversible erythroid differentiation after treatment of CML cell line K562 with new doxorubicin derivatives,” Biochemical Pharmacology, vol. 73, no. 2, pp. 175–184, 2007. View at Publisher · View at Google Scholar · View at Scopus
  93. L. E. Rajagopalan and J. S. Malter, “Regulation of eukaryotic messenger RNA turnover,” Progress in Nucleic Acid Research and Molecular Biology, vol. 56, pp. 257–286, 1997. View at Publisher · View at Google Scholar · View at Scopus
  94. J. Yuan, E. Angelucci, G. Lucarelli et al., “Accelerated programmed cell death (apoptosis) in erythroid precursors of patients with severe β-thalassemia (Cooley's anemia),” Blood, vol. 82, no. 2, pp. 374–377, 1993. View at Google Scholar · View at Scopus
  95. E. Angelucci, G. Lucarelli, J. Yuan et al., “Programmed cell death (PCD) and ineffective erythropoiesis in Cooley's anemia,” Blood, vol. 88, article 22, 1996. View at Google Scholar
  96. F. Centis, L. Tabellini, G. Lucarelli et al., “The importance of erythroid expansion in determining the extent of apoptosis in erythroid precursors in patients with β-thalassemia major,” Blood, vol. 96, no. 10, pp. 3624–3629, 2000. View at Google Scholar · View at Scopus
  97. T. J. Ley, J. DeSimone, N. P. Anagnou et al., “5-Azacytidine selectively increases γ-globin synthesis in a patient with β+ thalassemia,” The New England Journal of Medicine, vol. 307, no. 24, pp. 1469–1475, 1982. View at Publisher · View at Google Scholar · View at Scopus
  98. A. W. Nienhuis, T. J. Ley, and R. K. Humphries, “Pharmacological manipulation of fetal hemoglobin synthesis in patients with severe β-thalassemia,” Annals of the New York Academy of Sciences, vol. 445, pp. 198–211, 1985. View at Publisher · View at Google Scholar · View at Scopus
  99. D. P. Liu, C. C. Liang, Z. H. Ao et al., “Treatment of severe β-thalassemia (patients) with myleran,” The American Journal of Hematology, vol. 33, no. 1, pp. 50–55, 1990. View at Publisher · View at Google Scholar · View at Scopus
  100. S. P. Perrine, B. A. Miller, D. V. Faller et al., “Sodium butyrate enhances fetal globin gene expression in erythroid progenitors of patients with Hb SS and β thalassemia,” Blood, vol. 74, no. 1, pp. 454–459, 1989. View at Google Scholar · View at Scopus
  101. S. P. Perrine, Y. M. Yang, A. Piga et al., “Butyrate + EPO in beta thalassemia intermedia: interim findings of a phase II trial,” Blood, vol. 100, p. 47a, 2002. View at Google Scholar
  102. H. Fathallah, M. Sutton, and G. F. Atweh, “Pharmacological induction of fetal hemoglobin: why haven't we been more successful in thalassemia?” Annals of the New York Academy of Sciences, vol. 1054, pp. 228–237, 2005. View at Publisher · View at Google Scholar · View at Scopus
  103. M. H. Steinberg, Z. Lu, F. B. Barton, M. L. Terrin, S. Charache, and G. J. Dover, “Fetal hemoglobin in sickle cell anemia: determinants of response to hydroxyurea. Multicenter Study of Hydroxyurea,” Blood, vol. 89, no. 3, pp. 1078–1088, 1997. View at Google Scholar · View at Scopus
  104. S. Fucharoen, N. Siritanaratkul, P. Winichagoon et al., “Hydroxyurea increases hemoglobin F levels and improves the effectiveness of erythropoiesis in β-thalassemia/hemoglobin E disease,” Blood, vol. 87, no. 3, pp. 887–892, 1996. View at Google Scholar · View at Scopus
  105. Y.-T. Zeng, S.-Z. Huang, Z.-R. Ren et al., “Hydroxyurea therapy in β-thalassaemia intermedia: improvement in haematological parameters due to enhanced β-globin synthesis,” British Journal of Haematology, vol. 90, no. 3, pp. 557–563, 1995. View at Publisher · View at Google Scholar · View at Scopus
  106. F. M. Hajjar and H. A. Pearson, “Pharmacologic treatment of thalassemia intermedia with hydroxyurea,” Journal of Pediatrics, vol. 125, no. 3, pp. 490–492, 1994. View at Publisher · View at Google Scholar · View at Scopus
  107. D. Azoulay, A. Lavie, N. Horowitz et al., “A phase 2 study of HQK-1001, an oral fetal haemoglobin inducer, in β-thalassaemia intermedia,” British Journal of Haematology, vol. 164, pp. 451–464, 2014. View at Google Scholar
  108. Z. Wu, Y. Liu, X. Zhang et al., “Treatment of β-thalassemia with Bushen Yisui therapy: a randomized controlled trial,” Journal of Chinese Integrative Medicine, vol. 5, no. 2, pp. 137–140, 2007. View at Publisher · View at Google Scholar · View at Scopus